Citations

Clear

6273 citation(s) found for "To, Andrew".

Establishment of a canine urothelial carcinoma‐derived organoid biobank: A platform for comparative and translational research
Zdyrski, Christopher , Pawlak, Aleksandra , Nicholson, Hannah, Corbett, Megan P. , Catucci, M., Cheville, John, Cho, H, Melvin, Bryan J. , Peng, Jiayi, Saba, Corey , Hamsher, Hayden, Friedenberg, Steven G. , Mochel, Jonathan P. , Nicholson, Hannah F , Woodward, Andrew P , Douglass, Eugene , Mochel, Jonathan P , Allenspach, Karin , Zdyrski, Christopher , Pawlak, Aleksandra , Cheville, John C.

Mayo Clinic

Clinical and Translational Medicine | March 27, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1002/ctm2.70645 | PMID 41889014 Get It

Artificial intelligence‐based statistical modeling delineates architectural distortion in focal cortical dysplasia
Cannon, Andrew , Tian, Roland, Ebner, Blake , Burkett, Brian J. , Gompel, Jamie Van, Hartley, Christopher P., Moreira, Roger K. , Raghunathan, Aditya, Gompel, Jamie J. Van , Burkett, Brian , Van Gompel, Jamie J , Wong-Kisiel, Lily C. , Watson, Robert E., Wong‐Kisiel, Lily C. , Hartley, Christopher P.

Mayo Clinic

Brain Pathology | March 26, 2026 | Volume: 36 | Issue: 5 | Pages: No page available

10.1111/bpa.70096 | PMID 42767799 Get It

Abstract In epilepsy patients lacking magnetic resonance imaging‐visible lesions such as focal cortical dysplasia (FCD), surgical resections target regions with abnormal electroencephalographic (EEG) activity. However, histopathological identification of subtle cortical architectural abnormalities in these specimens remains challenging. We investigated whether artificial intelligence (AI)‐based morphometric and spatial analysis of NeuN‐stained cortical sections could detect neuronal architectural disorganization in epilepsy resections, including regions without definitive histologic dysplasia. Whole slide images were generated from 83 FCD regions and 19 neurologically normal autopsy controls. Regions of interest were annotated in QuPath as FCD, FCD‐adjacent, FCD‐distant, apparently normal (abnormal EEG without histologic dysplasia), and true normal (autopsy controls). NeuN‐positive neurons were detected using QuPath (90% sensitivity, 12% false positive rate). Spatial and morphometric features—including neuronal clustering, distribution inhomogeneity, and nuclear morphology—were extracted and used to train a multinomial, Least Absolute Shrinkage and Selection Operator‐regularized regression classifier. The classifier achieved 70.6% accuracy in subregion classification and 88.2% accuracy in overall specimen diagnosis. Notably, regions with abnormal EEG but lacking histologic dysplasia exhibited quantifiable architectural disorganization similar to those seen in areas adjacent to FCD and distinct from control tissue. AI‐driven analysis of neuronal morphology and spatial distribution reveals subtle cortical disorganization in epilepsy resections, including in histologically ambiguous regions. Further investigation is warranted to determine if this methodology can enhance the diagnostic yield of neuropathological evaluation and support more precise surgical targeting in epilepsy.
Case Report: Spinal cord stimulation for phantom limb pain facilitates upper limb myoelectric prosthesis use
Penz, Lauren E., Nelson, Andrew W. , Smither, F. Clay, Smither, F. Clay , Nelson, Andrew W., Hagedorn, Jonathan M.

Mayo Clinic

Frontiers in Pain Research | March 26, 2026 | Volume: 7 | Issue: No issue available | Pages: No page available

10.3389/fpain.2026.1751694 | PMID 41970636 Get It

Introduction This case describes the application of spinal cord stimulation for the treatment of phantom limb pain in a patient with a left transhumeral amputation. Treatment of pain involving a high frequency spinal cord stimulator allowed the patient to utilize his myoelectric prosthesis and improve his overall function. Clinical findings Severe, phantom limb pain with associated involuntary muscle contractions prevented the patient from wearing a prosthesis for more than three hours per day. He also had difficulty using his myoelectric prosthesis to use his left upper extremity for functional tasks. Therapeutic intervention A high frequency spinal cord stimulator was placed at the level of the cervical spine. The patient had improvement in pain and overall function. He was also able to tolerate wearing his prosthesis longer each day. Conclusion High frequency spinal cord stimulation may be an effective treatment option for individuals with phantom limb pain. Treatment of phantom limb pain may decrease barriers to prosthesis use and improve overall function.
Histologic and immunohistochemical characterization and frequency of rare subtypes of canine invasive urothelial carcinoma
Corbett, Megan P. , Elbadawy, Mohamed , Cheville, J., Wickham, Hannah , Nicholson, Hannah, Catucci, M., Melvin, Bryan J. , Ahmed, Basant H. , Zdyrski, Christopher , Oliveira, Lilian, Howerth, Elizabeth W. , Fasina, Olufemi , Mochel, Jonathan P. , Woodward, Andrew P , Nicholson, Hannah F , Catucci, Michael , Melvin, Bryan J , Zdyrski, Christopher , Howerth, Elizabeth W , Pawlak, Aleksandra , Fasina, Olufemi , Mochel, Jonathan P , Pawlak, Aleksandra , Allenspach, Karin

Mayo Clinic

Veterinary Pathology | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/03009858261428496 | PMID 41879030 Get It

While most cases of human muscle-invasive bladder cancer (MIBC) are diagnosed as conventional urothelial carcinoma (UC), there is growing recognition of histologic subtypes and divergent differentiation within conventional UC. In this study, 31 dogs with UC (33 slides) were evaluated for histologic subtypes and divergent differentiation, as specified by the recent World Health Organization update on the classification of urinary bladder cancers. Slides were reviewed by a medical uropathologist and 3 board-certified veterinary pathologists and assessed for expression of uroplakin III, vimentin, and E-cadherin. All tumors were classified as UC. Fifteen cases were identified as conventional UC. Among the remainder, 8 displayed glandular differentiation, 4 were classified as sarcomatoid UC, 2 showed squamous differentiation, 1 case was classified as a large nested subtype, and 1 case was classified as a tubular/microcystic subtype. This study found a higher frequency of certain histologic subtypes and divergent differentiation in canine UC, particularly sarcomatoid UC and UC with glandular differentiation, compared to previous reports of both canine UC and human MIBC. The relatively high prevalence of the sarcomatoid UC and UC with glandular differentiation in dogs observed in this study suggests that canine UC may serve as a valuable translational model for evaluating novel therapeutic agents, particularly for these rare and aggressive subtypes in humans.
The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus
Goldberg, Joseph F. , McIntyre, Roger S. , Mago, Rajnish, Jha, Manish K. , Berk, Michael , Kasper, Siegfried , Freeman, Marlene P. , GITLIN, MICHAEL J., Ostacher, Michael J. , Citrome, Leslie, Iosifescu, Dan V., Thase, Michael E., Young, Allan H. , Tohen, Mauricio, Nierenberg, Andrew A., Macaluso, Matt, Shelton, Richard C., Correll, Christoph U., Rosenblat, Joshua D., Gorwood, Philip, Khan, Arifulla, Kupka, Ralph, Cohen, Lawrence J., Mitchell, Philip B., Frye, Mark A., Sanacora, Gerard, Kane, John M., D, Goodman, Zohar, Joseph, Davis, Lori, Gupta, Swapnil , Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H., Cohen, Lawrence J. , McIntyre, Roger S , Malhi, Gin S , Jha, Manish K , Berk, Michael , Kasper, Siegfried , Sajatovic, Martha , Ostacher, Michael J , Perlis, Roy H , Furukawa, Toshi A , Vieta, E , Young, Allan H , Aaronson, Scott T , Rubio, Jose M , Swartz, Holly A. , Malhi, Gin S. , Gitlin, Michael , Citrome, Leslie , Vieta, Eduard , Thase, Michael E. , Tohen, Mauricio , Nierenberg, Andrew A. , Shelton, Richard C. , Correll, Christoph Ulrich , Rosenblat, Joshua D. , Gorwood, Philip , Kupka, Ralph , Mitchell, Philip B , Frye, Mark A. , Sanacora, Gerard , Kane, John M., Zohar, Joseph , Davis, Lori L. , Gupta, Swapnil, Zarate, Carlos A. , Clayton, Anita H.

Mayo Clinic

The British Journal of Psychiatry | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1192/bjp.2026.10580 | PMID 41877318 Get It

Summary The American Society of Clinical Psychopharmacology convened a 45-member international expert task force to identify circumstances supporting the deprescribing of core psychotropic medications for major depressive disorder (MDD) and bipolar disorders. Three Delphi survey rounds plus a selective literature review identified points of consensus (predefined as ≥75% agreement) about when antidepressant, antipsychotic, mood stabiliser and sedative-hypnotic deprescribing is warranted. Twenty out of 32 statements (63%) achieved consensus across seven thematic areas. In MDD, panellists favoured discontinuing antidepressants when mechanisms of action are duplicative, adequate trials produce ≤25% improvement or loss of prior efficacy cannot be regained through dose increases or augmentations. Indefinite antidepressant maintenance in MDD was favoured after three or more lifetime episodes. In bipolar disorder, antidepressant deprescribing was favoured in the setting of rapid cycling, mixed features or emerging mania/hypomania symptoms; and discouraged if prior antidepressant cessation led to relapse. In nonpsychotic mood disorders, panellists favoured deprescribing antipsychotics that caused significant weight gain or tardive dyskinesia over adding pharmacological antidotes. Deprescribing to achieve an eventual medication-free status was considered inappropriate, in bipolar type 1, but not necessarily bipolar type 2 disorder. Although individualised circumstances necessarily inform psychopharmacology management, clinical presentations that misalign with existing pharmacotherapies may signal the desirability of cautious deprescribing.
Population‐Based Epidemiology of Autoimmune Seizures and Epilepsies
Thakolwiboon, Smathorn , Wood, Kathryne N., Paramasivan, Naveen, Smith, Kelsey M., Dasari, Surendra, Devine, Michelle F., McKeon, Andrew , Ζεκερίδου, Αναστασία , Flanagan, Eoin P., Pittock, Sean J., Dubey, Divyanshu , Stabile, Andrea , McKeon, Andrew , Zekeridou, Anastasia , Dubey, Divyanshu , Thakolwiboon, Smathorn , Paramasivan, Naveen Kumar , Britton, Jeffrey W. , Smith, Kelsey M. , DASARI, SURENDRA, Flanagan, Eoin P. , Pittock, Sean J.

Mayo Clinic

Annals of Neurology | March 25, 2026 | Volume: 100 | Issue: 1 | Pages: 74-83

10.1002/ana.78204 | PMID 41876839 Get It

Objective To estimate the prevalence, incidence, and disease burden of autoimmune seizures and epilepsies in Olmsted County. Methods We conducted a retrospective, population‐based study using the Rochester Epidemiology Project (1996–2019). Age‐ and sex‐standardized rates (2019 United States standard population) per 100,000 were calculated with 95% confidence intervals (95% CIs). Temporal trends in incidence were assessed over 3 consecutive 8‐year intervals (1996–2003, 2004–2011, and 2012–2019) using Poisson regression to estimate rate ratios per period and trend. Disability‐adjusted life years (DALYs), years of life lost (YLL), and years lived with disability (YLD) and 95% uncertainty intervals (95% UIs) were estimated for 2019. Results Twenty‐three patients were identified between 1996 and 2019. In 2019, the standardized prevalence of all autoimmune seizures and epilepsies was 9.81 (95% CI, 5.59–15.21) per 100,000, including autoimmune‐associated epilepsy (AAE) 7.27 (3.74–11.95) and acute symptomatic seizures secondary to autoimmune encephalitis (ASSAE) 2.55 (0.69–5.60). From 1996 to 2019, the standardized incidence was 0.50 (0.29–0.77) per 100,000 person‐years overall, with AAE 0.36 (0.19–0.59) and ASSAE 0.15 (0.05–0.30). By period, the standardized incidence of all autoimmune seizures and epilepsies suggested a rising trend from 0.28 (95% CI, 0.06–0.68) in 1996 to 2003 to 0.60 (95% CI, 0.24–1.12) in 2004–2011, then plateaued at 0.53 (95% CI, 0.21–1.00) in 2012 to 2019 (rate ratio per 8‐year interval 1.30, 95% CI, 0.71–2.38), largely driven by the seropositive subgroup. The standardized DALY rate was 26.27 (95% Uncertainly intervals [UI], 5.30–67.09) per 100,000 (YLL 20.07 [0.00–60.21] and YLD 6.20 [5.06–7.39]). Interpretation Although autoimmune seizures and epilepsies remain rare, they result in a disproportionately high disease burden. ANN NEUROL 2026;100:74–83
Brain-Only Versus GI-Only Synucleinopathy: A Comprehensive Autopsy Study With Both IHC and SAA
Orru, Christina D., Beach, Thomas G., Adler, Charles H., Shill, Holly A., Driver-Dunckley, Erika, Mehta, Shyamal H. , Atri, Alireza, Lorenzini, Ileana , Qiji, Sanaria H., Intorcia, Anthony J., Hughson, Andrew G., Groveman, Bradley R. , King, Samantha, Parveen, Sabiha , Caughey, Byron, Serrano, Geidy E , Orru, Christina Doriana , Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Atri, Alireza , Hughson, Andrew G. , Alam, Parvez , Vascellari, Sarah , Caughey, Byron W. , Serrano, Geidy E.

Mayo Clinic

No container title available | March 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.18.26348355 | PMID 41929295 Get It

ABSTRACT Braak and others have proposed that Lewy body pathology (LBP) in Parkinson’s disease (PD) may arise not only in the brain but alternatively from an initial site in the gastrointestinal (GI) tract with subsequent passage to the central nervous system CNS through the vagus nerve or other routes. We tested this hypothesis by using both immunohistochemistry (IHC) and RT QuIC a form of alpha synuclein seed amplification assay (SAA) to detect alpha synuclein LBP in samples from selected brain regions and 10 GI tract sites taken from autopsies of 50 PD subjects and 128 elderly subjects without parkinsonism or dementia including 34 with IHC identified CNS incidental Lewy body disease (ILBD) and 94 with no Lewy body IHC pathology detected (NLB). A positive SAA or IHC result was restricted to the GI tract in only 2 subjects while LBP by either SAA or IHC was restricted to the brain in 11 subjects. To fairly compare GI-only with brain-only synucleinopathy, however, we would have to do SAA on brain samples from all ILBD and NLB cases in at least 4 critical brain regions: olfactory bulb, medulla, pons, and amygdala. Further SAA of brain regions is estimated, based on the proportional results to date, to potentially identify 21 additional brain-only LBP subjects, for a total of 32, if it were done on all of the NLB subjects. From this brain-only LBP is estimated to be 16 times more common than GI-only LBP. To assess the clinical impact of SAA-positive GI sites we found that the number of positive sites per subject is significantly correlated with UPDRS motor score and SCOPA-AUT GI related scores including those for salivation, straining, constipation, and bowel movement.
777: EFFECT OF STEROIDS ON CYSTATIN C AND ESTIMATED GLOMERULAR FILTRATION RATE IN HOSPITALIZED PATIENTS
Williams, Victoria, Gerlach, Anthony, Cole, Kristin, Barreto, Jasón, Hernandez, Brandy, Kashani, Kianoush, Rule, Andrew, Wieruszewski, Patrick, Barreto, Erin, Gerlach, Anthony Thomas , Rule, Andrew D. , Wieruszewski, Patrick M. , Frazee, Erin N.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001185104.35935.bf Get It